Needham Reiterates Buy on DocGo, Maintains $3 Price Target
Needham analyst Ryan MacDonald reiterates DocGo (NASDAQ:DCGO) with a Buy and maintains $3 price target.
Read original at benzingaStocks · News reference
DocGo shares are trading lower after the company reported worse-than-expected Q2 financial results and narrowed its FY2026 sales guidance.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 2:28 PM
- Checked
- Aug 18, 2026, 2:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Transcript: DocGo Q2 2026 Earnings Conference Call
DocGo (NASDAQ:DCGO) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
Read original at benzinga12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.
Read original at benzinga